...
首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design.
【24h】

Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design.

机译:充血性心力衰竭和心房颤动(AVERT-AF)患者的房室结消融再同步治疗研究设计。

获取原文
获取原文并翻译 | 示例
           

摘要

Atrial fibrillation (AF) and congestive heart failure (CHF) affect millions of patients in the United States. Several studies suggest that AF and in particular the irregular ventricular response might be contributing to the left ventricular dysfunction. Studies that compared pharmacologic rate control to atrioventricular junction (AVJ) ablation followed by right ventricular pacing which restores a regular ventricular response, failed to show an improvement when compared to pharmacological rare control. These results might be explained by the fact that while AVJ ablation restored a regular ventricular response, it subjected patients to the detrimental effects of RV apical pacing. The AVERT-AF trial (Atrio-VEntricular Junction Ablation Followed by Resynchronization Therapy in patients with CHF and AF) is a prospective, randomized, double-blinded, multicenter trial that will be testing the hypothesis that AVJ ablation followed by biventricular pacing significantly improves exercise capacity and functionalstatus compared to pharmacologic rate control in patients with chronic AF and depressed ejection fraction, regardless of rate or QRS duration. A total of 180 patients will be enrolled to test the primary endpoint, which is exercise duration. Patients_enrollment will begin in summer 2006 and is expected to be completed in 2008. The results of this trial should help define the best treatment option for this common arrhythmia in patients with left ventricular dysfunction.
机译:心房颤动(AF)和充血性心力衰竭(CHF)影响美国成千上万的患者。多项研究表明,AF,尤其是不规则的心室反应可能是导致左心功能不全的原因。将药理学速率控制与房室交界处消融后再进行右心室起搏(恢复正常的心室反应)进行比较的研究未能显示出与药理学上的罕见对照相比没有改善。这些结果可以通过以下事实来解释,即AVJ消融可恢复正常的心室反应,但会使患者遭受RV心尖起搏的不利影响。 AVERT-AF试验(对CHF和AF患者进行房室结消融再同步治疗)是一项前瞻性,随机,双盲,多中心试验,将检验AVJ消融后双心室起搏显着改善运动的假说。慢性心房颤动和射血分数降低的患者,与药理学速率控制相比,无论其速率或QRS持续时间如何,其容量和功能状态均得到了比较。总共180名患者将参加测试主要终点,即运动持续时间。患者注册将于2006年夏季开始,预计于2008年完成。该试验的结果应有助于确定左心功能不全患者这种常见心律失常的最佳治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号